4D MOLECULAR THERAPEUT

4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022

03 Nov 2022 08:45:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022

26 Oct 2022 15:05:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer

27 Sep 2022 15:10:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

20 Sep 2022 15:15:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update

11 Aug 2022 15:03:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences

02 Jun 2022 15:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

12 May 2022 15:01:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference

05 May 2022 15:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis

04 Apr 2022 15:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights

28 Mar 2022 15:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company’s Board of Directors

22 Feb 2022 15:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

11 Feb 2022 15:03:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium

09 Feb 2022 07:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Present Updated Clinical Data with 4D-310 in Fabry Disease Patients in Platform Presentation at the 18th Annual WORLDSymposium

02 Feb 2022 15:01:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa

10 Jan 2022 07:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD

06 Jan 2022 15:03:04 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference

23 Nov 2021 15:05:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights

10 Nov 2021 15:01:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock

28 Oct 2021 20:06:48 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

26 Oct 2021 16:52:14 By Nasdaq GlobeNewswire